Washington D.C. – Moderna, a leading biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has issued a refusal-to-file (RTF) letter for its investigational mRNA vaccine for influenza, mRNA-1010. The decision, delivered by the FDA’s Center for Biologics Evaluation and Research (CBER), marks a significant setback for Moderna’s ambitions to expand its mRNA technology beyond COVID-19 into the seasonal flu market and has raised questions about regulatory consistency and the broader landscape of vaccine policy under the current administration.
The RTF letter, a rare procedural hurdle, indicates that the FDA deems the application incomplete or not adequately structured for a substantive review. According to Moderna’s public statement on Tuesday, the sole reason cited for the refusal was the choice of a licensed standard-dose seasonal influenza vaccine as the comparator in its pivotal Phase 3 clinical trial. The FDA’s letter specifically pointed to the use of Fluarix, a standard-dose vaccine, and asserted that for adults over 65, the trial should have utilized a high-dose vaccine, which the agency now considers the “best-available standard of care” for this demographic. This stance, Moderna contends, is inconsistent with feedback received during multiple pre-Phase 3 and pre-submission consultations with CBER.
A Deep Dive into the Regulatory Rejection
Moderna’s mRNA-1010 vaccine represents a significant technological leap in influenza prevention. Unlike traditional flu vaccines that use inactivated or attenuated viruses, mRNA vaccines instruct the body’s cells to produce a specific viral protein, triggering an immune response. This platform gained global prominence with the rapid development and deployment of COVID-19 vaccines. The company had submitted its Biologics License Application (BLA) for mRNA-1010 with high hopes, having already seen the vaccine accepted for review by regulatory bodies in the European Union, Canada, and Australia. The U.S. refusal, therefore, introduces an unexpected divergence in global regulatory pathways for this novel vaccine.
The core of the FDA’s objection lies in the choice of comparator. For vaccine trials, a comparator arm is crucial for evaluating the new vaccine’s efficacy and safety relative to an existing, approved product. Moderna utilized Fluarix, a widely available standard-dose quadrivalent influenza vaccine. The FDA’s position, articulated in the RTF letter, asserts that for the critical demographic of adults aged 65 and older, a high-dose vaccine (such as Fluzone High-Dose Quadrivalent or Fluad Quadrivalent, which are adjuvanted) should have been the benchmark. High-dose and adjuvanted vaccines are often recommended for seniors due to their generally weaker immune responses, offering superior protection compared to standard-dose vaccines in this age group.
However, Moderna has pushed back against the FDA’s rationale, stating that neither existing regulations nor the FDA’s published guidance documents explicitly mandate the use of a comparator reflecting the "best-available standard of care." The company emphasized that the letter did not identify any specific safety or efficacy concerns regarding mRNA-1010 itself, suggesting the issue is purely procedural regarding trial design. This procedural disagreement has far-reaching implications, particularly for a company that has invested heavily in developing and bringing innovative mRNA vaccines to market.
Moderna’s Clinical Data and Regulatory Engagement Timeline
Moderna’s Phase 3 trials for mRNA-1010 demonstrated promising results. The vaccine achieved a 26.6% higher relative vaccine efficacy compared to the standard-dose comparator. Breaking down the efficacy by individual strains, mRNA-1010 showed 29.6% efficacy for A/H1N1, 22.2% for A/H3N2, and 29.1% for B/Victoria strains. Crucially, in the demographic of adults 65 and older, the vaccine demonstrated 27.4% relative efficacy. These figures suggest that mRNA-1010 could offer enhanced protection over conventional standard-dose vaccines, potentially addressing a significant public health need, especially among vulnerable populations.
The timeline of Moderna’s engagement with CBER further highlights the company’s surprise at the RTF. In April 2024, Moderna submitted its Phase 3 study protocol to CBER for review. While CBER did recommend considering a high-dose vaccine for the comparator arm in adults over 65 at that time, Moderna states that the agency did not raise any formal objections or issue clinical hold comments concerning the adequacy of the trial design. Following the completion of the trial, Moderna also conducted a pre-submission meeting with CBER, a standard practice to discuss the BLA package and ensure its completeness before formal submission. According to Moderna, CBER gave no indication during this meeting that it would refuse to review the vaccine application. This perceived inconsistency between prior guidance and the final RTF letter is at the heart of Moderna’s appeal.
Moderna CEO Stéphane Bancel expressed strong dissatisfaction with the decision, stating, “It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting. We look forward to engaging with CBER to understand the path forward as quickly as possible so that America’s seniors, and those with underlying conditions, continue to have access to American-made innovations.” The company has formally requested a meeting with the FDA to resolve the issue and determine a path forward.
The Rarity of Refusal-to-File Letters
Refusal-to-file letters are an uncommon occurrence in the FDA’s drug and vaccine approval process. A 2021 study examining 2,475 applications found that only approximately 4% received an RTF letter. This rarity underscores the unusual nature of the FDA’s decision regarding mRNA-1010 and suggests a departure from routine practice, especially given Moderna’s prior consultations with the agency. RTF letters typically signify fundamental flaws in the application, such as missing critical data, incorrect formatting, or a trial design that is deemed insufficient from the outset. The fact that the RTF was issued solely on the grounds of comparator choice, despite prior discussions, amplifies the industry’s concern about regulatory predictability.
Political Undercurrents and Leadership Influence
The decision comes amidst a period of significant shifts in U.S. vaccine policy, notably under the Trump administration, with Robert F. Kennedy Jr. serving as the Secretary of Health and Human Services (HHS). Kennedy, a long-time vaccine skeptic, assumed office in February 2025 and has overseen substantial changes to the nation’s vaccine strategy. His appointment and subsequent policy actions have been viewed with alarm by public health experts and vaccine advocates, who fear a weakening of evidence-based public health initiatives.
Further scrutinizing the decision, the RTF letter was signed by Dr. Vinay Prasad, the Director of CBER. Dr. Prasad has been a vocal critic of mRNA vaccines, particularly regarding their widespread use and certain aspects of their regulatory review during the COVID-19 pandemic. His appointment to lead CBER, a critical division responsible for regulating vaccines and other biologics, raised concerns among some scientific and public health communities due to his past critiques. The alignment of his known skepticism with this specific RTF decision has led to speculation about potential political or ideologically driven influence on regulatory processes.
Adding another layer to this narrative, a report by STAT, a prominent health and medicine news outlet, revealed internal discord within the FDA regarding the mRNA-1010 application. According to STAT, Dr. Prasad overruled the agency’s career reviewers in making this decision. Three agency officials familiar with the matter reportedly told STAT that the team of career scientists was prepared to review Moderna’s application. Furthermore, David Kaslow, the head of the vaccine office within CBER, is said to have authored a detailed memo explaining why the FDA should proceed with the review, indicating a clear disagreement between senior leadership and scientific staff. This reported internal clash suggests that the RTF might not be a unanimous scientific consensus but rather a top-down directive, fueling concerns about the politicization of scientific review processes.
Broader Implications: Innovation, Public Health, and Policy
If approved, mRNA-1010 would be the first mRNA-based influenza vaccine on the market, representing a significant advancement in flu prevention technology. The potential benefits of mRNA flu vaccines include faster manufacturing capabilities, adaptability to emerging strains, and potentially enhanced efficacy compared to conventional vaccines. The FDA’s refusal to review, therefore, has broader implications beyond just Moderna’s product pipeline.
The decision is part of a pattern observed under the Kennedy administration, which has seemingly adopted a more skeptical stance toward mRNA vaccine technology and its development. In August 2025, HHS canceled $500 million in BARDA (Biomedical Advanced Research and Development Authority) funding specifically allocated for mRNA vaccine development. BARDA is a federal agency responsible for securing medical countermeasures against public health emergencies, and its funding is crucial for innovation. This cancellation sent a chilling signal to biotech companies heavily invested in mRNA platforms. Moreover, in December 2025, Children’s Health Defense, an organization founded by Robert F. Kennedy Jr., formally petitioned the FDA to revoke the licenses for Moderna and Pfizer’s COVID-19 mRNA vaccines. These actions collectively paint a picture of an administration actively seeking to curtail the influence and deployment of mRNA vaccine technology, rather than fostering its growth.
The delay in reviewing mRNA-1010 could hinder efforts to improve flu vaccine efficacy, particularly for vulnerable populations like seniors. Seasonal influenza remains a significant public health burden, causing millions of illnesses, hundreds of thousands of hospitalizations, and tens of thousands of deaths annually in the U.S. alone. Innovations that offer improved protection are critical to mitigating this impact. A prolonged delay in the approval of a potentially superior vaccine could mean missed opportunities to prevent illness and save lives.
Furthermore, this episode could have a chilling effect on pharmaceutical companies investing in novel vaccine technologies. The unpredictability of regulatory pathways, especially when prior consultations seem to be contradicted by final decisions, can deter innovation. Companies rely on clear, consistent guidance from regulatory bodies to plan clinical trials and allocate substantial resources. If such guidance is subject to change or overruled without clear justification, it introduces significant risk and uncertainty, potentially slowing the pace of drug discovery and development.
The Path Forward for Moderna
Moderna is now in a critical phase of engagement with the FDA. The requested meeting with CBER will be pivotal in understanding the specific requirements the agency now demands and whether a resubmission with an amended trial design or a re-analysis of existing data (perhaps focusing on the younger adult cohort where the comparator was deemed acceptable) could satisfy the FDA’s concerns. Alternatively, Moderna may need to conduct additional clinical trials with a high-dose comparator arm for older adults, which would entail significant time and financial investment, delaying potential market entry by years.
The company’s ability to successfully navigate this regulatory challenge will not only determine the future of mRNA-1010 in the U.S. but also serve as a barometer for the broader regulatory environment facing mRNA vaccine developers. The outcome of this dispute will undoubtedly be watched closely by the pharmaceutical industry, public health organizations, and policymakers alike, as it could signal a shift in how innovative vaccine technologies are evaluated and brought to market in the United States. The tension between fostering innovation and ensuring rigorous, consistent regulatory standards is now sharply in focus, with profound implications for public health.
Leave a Reply